An NF1 result needs a specimen, an exact variant and a clinical interpretation. Finding the gene name on a tumor panel, an inherited-disease report or a research paper does not make those findings equivalent. This guide provides a structured way to identify what the result actually establishes.
In this guide: What does neurofibromin do? · Read the report in five passes · Can a genetic result replace diagnostic reasoning? · What does mosaic NF1 mean? · What should I ask about an unresolved test? · How to evaluate an NF1 experiment · Turn the report into a focused discussion
What does neurofibromin do?
NF1 encodes neurofibromin, a tumor-suppressor protein that helps restrain RAS-related growth signaling. Disruption can affect growth regulation. The surrounding cells and tissue context also matter in neurofibroma biology; a simple signaling diagram is not a complete account of tumor formation. [1]
Keep the normal protein function separate from the effect of a specific variant. Knowing that a gene participates in a pathway is the beginning of an evidence review. It does not tell you that every sequence change in that gene disrupts the pathway or causes a particular phenotype.
Read the report in five passes
- Purpose and sample: identify whether testing investigated a constitutional condition, a tumor or another question.
- Exact identity: retain the transcript/version, DNA and protein notation, or the coordinates of a deletion or duplication.
- Classification: record pathogenic, likely pathogenic, uncertain or another classification exactly as stated.
- Detection limits: ask which sequence and copy-number changes were assessed and whether mosaicism was within scope.
- Clinical integration: record how the laboratory result fits the person’s findings and which questions remain unresolved.
NF1 can involve a wide range of features and variable expression. A molecular finding should be interpreted alongside the clinical assessment rather than used as a complete description of the person. [2]
Can a genetic result replace diagnostic reasoning?
The revised NF1 criteria incorporate a pathogenic NF1 variant in an appropriate clinical setting and distinguish constitutional and mosaic presentations. They also address overlap with Legius syndrome. An uncertain variant should not be substituted for the pathogenic-variant criterion. [3]
Hypothetical report comparison: one report contains a pathogenic NF1 finding in an appropriate non-tumor specimen; another lists an uncertain NF1 change found only during tumor profiling. Before writing “both people have inherited NF1,” identify the missing clinical and constitutional evidence. The two reports begin different investigations.
Read tumor versus germline testing and the ACMG/AMP framework for the broader distinction between identifying a change, classifying it and establishing a diagnosis.
What does mosaic NF1 mean?
Mosaicism means a variant is present in some cells rather than uniformly throughout the body. Mosaic NF1 may be localized or more widespread; a blood result may not capture every relevant tissue. Testing strategy and family counseling need specialist interpretation. A person with mosaic NF1 can have a child with non-mosaic NF1. [4]
Ask what the specimen can answer. Record whether the laboratory measured a variant allele fraction, how the assay was validated and what detection limit applies. Do not turn a percentage in one sample into an unsupported estimate of the percentage of the entire body affected.
What should I ask about an unresolved test?
A practical follow-up request is: “Does this result adequately address the suspected mechanism and the tissue question, and what remains outside its scope?” The answer might identify a technical limit, an alternative diagnosis, a need for clinical follow-up or a more focused investigation. It should come from the responsible clinical and laboratory team.
Keep “not detected,” “not assessed,” “uncertain” and “not clinically suspected” as separate categories in a worksheet. They are different kinds of information. Our test-limits guide and RNA sequencing guide provide questions for discussing assay scope.
How to evaluate an NF1 experiment
- Was the experiment conducted in a cell model, tumor tissue or a clinical cohort?
- Was the exact variant studied or was the gene altered in another way?
- What measurement represents pathway activity, and how was it validated?
- Were appropriate controls and independent replicates included?
- Does the evidence concern biological mechanism, variant classification or treatment response?
- Which conclusions depend on assumptions beyond the experiment?
For a journal club, assign separate columns to observation and interpretation. “The assay changed under these conditions” is an observation; “this predicts every patient’s outcome” is a much broader claim that needs additional evidence. Preserve that difference in summaries and presentations.
Turn the report into a focused discussion
Prepare a one-page summary with the testing question, exact finding, laboratory interpretation, clinical features and unresolved issues. Bring the original report as well. Avoid uploading identifiable patient information to general search tools.
Continue with the NF1 disease guide and how to investigate conflicting variant assertions. Use the variant research assistant, literature tools and care finder to organize evidence and locate professional directories. These tools do not diagnose NF1 or calculate personal tumor risk.
Educational information, not an individual diagnosis or treatment plan. The current specialist-review status appears above. Illustrations are original educational examples, not patient records.